Northern Star Investment Stock (OTC: NSTB)

Northern Star Investment Stock (OTC:NSTB), Trade Ideas

Northern Star Investment Corp II is a blank check company established the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Penny Stocks

Small Cap

Markets

Trading Ideas

Bakkt Holdings, Inc. Class A Common Stock

BKKT

HOOD

NSTB

Digital asset platform company Bakkt Holdings Inc (NYSE: BKKT) announced it is acquiring Apex Crypto from Apex Fintech Solutions for a total purchase price of $200 million.

Bakkt To Acquire Apex Crypto: What Investors Should Know And Why It&#39;s Important

Fintech news covering the emerging Financial Technology services sector

Fintech

Health Care

General

HCIC

KVSA

PFDR

SCVX

TPGY

VELO

WYNN

Along with the hundreds of announced SPAC mergers and closed deals in 2021 came a handful of SPAC deals that were terminated. Here’s a look at what it means for the SPACs that called off mergers.

How The Net Asset Value Is Still In Place For SPACs With Terminated Deals

News

AAPL

AMZN

BNGO

CCIV

COIN

GBTC

MARA

MMAT

MSFT

PLTR

RIOT

TLRY

TSLA

WISH

A quarterly report from Apex Clearing shows what the top owned stocks are among Millenials and Gen Z. Here is a look at the top holdings and the biggest movers from the first quarter.

AMC Entertainment Tops Q2 Trends For Millenials And Gen Z, WISH Enters The Top 100

NORTHERN STAR INV II by Northern Star Investment Corp. II

Northern Star Investment Corp II

Guidance

MBOT

Microbot Medical Anticipates Receiving 510(K) Clearance From FDA In H1 2025, And CE MARK Approval In H2 2025

The repurchase authorization replaces all previous authorizations.&nbsp;The Board also elected&nbsp;Mandy Glew&nbsp;to serve as senior vice president and president, EMEA of the corporation. It declared a cash dividend of&nbsp;20 cents&nbsp;per share, payable&nbsp;June 17, 2024, to shareholders of record as of&nbsp;June 3, 2024.

Dividends

Buybacks

BALL

Ball Corporation's Board Approves Repurchase Of Up To Total Of 40M Shares Of Its Common Stock

Northrim BanCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIM#NASDAQ">NRIM</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.05 by 40.95 percent. This is a 76.19 percent increase over earnings of $0.84 per share from the same period last year.

Earnings

Earnings Beats

NRIM

Northrim BanCorp Q1 EPS $1.48 Beats $1.05 Estimate

First US Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUSB#NASDAQ">FUSB</a>) reported quarterly earnings of $0.34 per share. This is a 3.03 percent increase over earnings of $0.33 per share from the same period last year.

FUSB

First US Bancshares Q1 EPS $0.34 Up From $0.33 YoY

ESRT

Empire State Realty Trust Sees FY24 Core FFO $0.90-$0.94 Vs $0.92 Est.

QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) reported its first-quarter financial results after the bell Wednesday. Here's a <a href="https://www.benzinga.com/pressreleases/24/04/b38415713/quantumscape-reports-first-quarter-2024-business-and-financial-results">look at the details.&nbsp;</a>
The Details: QuantumScape reported quarterly losses of 24 cents per share which met the analyst consensus estimate and was unchanged from the same period last year.
The company ended the first quarter with $1.01 billion in liquidity and expects its cash runway to extend into the second half of 2026.
&#8220;We remain tightly focused on a singular goal: bringing our first commercial solid-state lithium-metal battery cell to market for electric vehicle applications. Achieving this ambitious goal requires three major elements: differentiated technology, close customer engagement and methodical execution of our milestones,&#8221; said QuantumScape CEO Dr. Siva Sivaram. 
Outlook:&nbsp;The company maintained its full-year 2024 guidance for capital expenditures to be between $70 million and $120 million and for adjusted EBITDA loss to be between $250 million and $300 million.
Related News: <a href="https://www.benzinga.com/news/24/04/38407505/whats-going-on-with-advanced-micro-devices-stock">What&#8217;s Going On With Advanced Micro Devices Stock?</a>
QS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, QuantumScape shares are down 2.55% after-hours at $5.34 at the time of publication Wednesday.
Image: Courtesy of QuantumScape Corporation

After-Hours Center

Movers

Tech

QuantumScape Reports Q1 Results: What's Next?

CONMED Corporation (NYSE:<a href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) today announced that Patrick Beyer, President of International and Global Orthopedics, has been promoted to the newly created role of Chief Operating Officer (COO), effective immediately. In this role, Mr. Beyer will take on additional responsibility for leading the Company's commercial businesses, as well as Operations, Distribution, Regulatory Affairs / Quality Assurance, and Customer Excellence.
"Pat has been invaluable in driving CONMED's above-market growth and expanding our presence in key markets," commented Curt R. Hartman, CONMED's Chair of the Board, President, and Chief Executive Officer. "He is an experienced leader with a proven track record of commercial and operational excellence and delivering results, and I look forward to Pat's continued impact on the organization."
"I am excited to take on this important leadership role at CONMED and to continue contributing to the Company's innovation and success," said Mr. Beyer. "I look forward to continuing to work with the team to build on CONMED's legacy of delivering high-quality products and creating value for physicians and patients around the world."
Mr. Beyer joined CONMED in 2014 as President of International. In October 2020, Mr. Beyer was promoted to President of International and Global Orthopedics, where he took on the added responsibilities for the Company's Global Orthopedics R&amp;D and U.S. Orthopedics commercial business. In 2022, Mr. Beyer led the process of acquiring both In2Bones and BioRez. Prior to CONMED, Mr. Beyer spent 21 years at Stryker in leadership roles of increasing progression and nearly four years as CEO of ICNet International. He holds a B.A. in Economics from Kalamazoo College and an M.B.A from Western Michigan University. Mr. Beyer also completed the Advanced Management Program at Harvard University.

Management

CNMD

CONMED Corporation Promotes Patrick Beyer To Chief Operating Officer, Effective Immediately

Third Coast Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.49 by 24.49 percent.

TCBX

Third Coast Bancshares Q1 2024 GAAP EPS $0.61 Beats $0.49 Estimate

WIIM

Community Health Systems shares are trading higher after the company reported better-than-expected Q1 financial results.

Inter Parfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) reported quarterly sales of $324.00 million which missed the analyst consensus estimate of $335.05 million by 3.30 percent. This is a 3.94 percent increase over sales of $311.72 million the same period last year.

Earnings Misses

IPAR

Inter Parfums Q1 Sales $324.00M Miss $335.05M Estimate

Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.31 by 0.76 percent. The company reported quarterly sales of $1.171 billion which beat the analyst consensus estimate of $1.122 billion by 4.36 percent. This is a 18.45 percent decrease over sales of $1.436 billion the same period last year.

LSTR

Landstar System Q1 2024 GAAP EPS $1.32 Beats $1.31 Estimate, Sales $1.171B Beat $1.122B Estimate

ORLY

O'Reilly Automotive shares are trading lower after the company reported Q1 financial results.

First Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBNC#NASDAQ">FBNC</a>) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.63 by 3.17 percent. This is a 64.86 percent increase over earnings of $0.37 per share from the same period last year.

FBNC

First Bancorp Q1 EPS $0.61 Misses $0.63 Estimate

CDTX

Cidara Therapeutics shares are trading higher after the company announced the divestiture of rezafungin to Mundipharma*, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing.

Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.18) by 33.33 percent. This is a 62.5 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $160.672 million which missed the analyst consensus estimate of $174.751 million by 8.06 percent. This is a 0.94 percent increase over sales of $159.174 million the same period last year.

Orion Gr Hldgs Q1 2024 Adj EPS $(0.12) Beats $(0.18) Estimate, Sales $160.672M Miss $174.751M Estimate

Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024. &nbsp;
Presentation Details:
Title: Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors Presenter: Dr. Shiraj Sen Session Type: Poster Session Session Title: Developmental Therapeutics—Immunotherapy Date and Time: Saturday, June 1, 2024, at 9:00 a.m. – 12:00 p.m. CDT Abstract Number: 2600

Biotech

SNSE

Sensei Biotherapeutics To Present Topline Clinical Data From The SNS-101 Phase I Dose Escalation Study At The 2024 ASCO Annual Meeting

OCEA

Ocean Biomedical Reports Receipt Of Notice From Nasdaq Regarding Late Filing Of Annual Report On Form 10-K

23andMe Holding Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting, taking place May 31 - June 4 in Chicago. 23andMe will present clinical data, including preliminary efficacy and exploratory biomarker analyses, for the neuroendocrine and ovarian cancer patient cohorts in the Phase 2a portion of its ongoing Phase 1/2a clinical trial. &nbsp;
23andMe scientists discovered the target for 23ME-00610 through the Company's proprietary database of human genetic and health information. 23andMe has more than 15 million genotyped customers, roughly 80 percent of whom consent to participate in research. By analyzing de-identified, aggregate genetic and health data from consented research participants, 23andMe identified genetic variants of CD200R1, CD200, and DOK2, the downstream signaling protein, associated with higher risks of immune disease and lower risks of cancer, pinpointing CD200R1 as a promising immuno-oncology target.
Additional preclinical data validated the CD200-CD200R1 pathway as an immune checkpoint, and potential target for reversing immune tolerance in cancer as a monotherapy, or in combination with other therapies. Clinical data from the dose escalation cohort of patients with advanced solid tumors has shown 23ME-00610 has favorable pharmacokinetics (PK) for dosing once every three weeks, expected on-target pharmacologic activity, and a promising safety and tolerability profile at the preliminary recommended phase 2 dose of 1400 mg.
Details on the posters are below. Posters will be available on the 23andMe <a href="https://www.globenewswire.com/Tracker?data=HUKuZt_DBrErpQ6L5XjkOtxNstVmE54Mggmvetbl46UFpQTrj4Z1pFJpp7RXhraeLVQLdNLp1t_lYX4PVKdyrzzoK5tSgvg-3R3cF85bQT8=">Therapeutics</a> and <a href="https://www.globenewswire.com/Tracker?data=sdw7eGZA9cyfgn17MiAcDk8rp8bkox-ieWnT506LxdlT3f1cU8wkR6MLovtu6SgEhkStsewwpJ69uHHF5yTGPWqBWMRclc2AdIR8OhNP9Ig=">Investor</a> websites following the presentations.
Abstract: 4129 Title: Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort. Session Type: Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Date and Time: June 1, 1:30 - 4:30 PM CDT
Abstract: 5575 Title: Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort. Session Type: Poster Session – Gynecologic Cancer Date and Time: June 3, 9:00 AM - 12:00 PM CDT
About 23ME-00610 23ME-00610 is a first-in-class anti-CD200R1 monoclonal antibody in the Phase 2a portion of Phase 1/2a clinical development for advanced solid malignancies. CD200R1 was identified as an immuno-oncology (IO) target from the 23andMe database, with pleiotropic causal variants that have opposing effect on risks for cancer and immune diseases, referred to as an IO signature, observed in 3 components in this pathway.
23ME-00610 is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenance of immune tolerance. CD200R1 is an inhibitory receptor expressed on T cells and myeloid cells while CD200, the ligand for CD200R1, is highly expressed on certain tumors. In preclinical studies, binding of tumor-associated CD200 to CD200R1 leads to immune suppression and decreased immune cell killing of cancer cells. Preclinical data indicate that this mechanism has the potential to restore the ability for both T-cells and myeloid cells to kill cancer cells. Clinical trials registry (clinicaltrials.gov): NCT05199272.

23andMe To Present Preliminary Efficacy And Biomarker Data For 23ME-00610 At The 2024 ASCO Annual Meeting

QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world's leading infectious disease killer.
Building on QIAGEN's ongoing efforts to support global TB management and control, which include the leading diagnostics test QuantiFERON-TB Gold Plus, the new panel enables culture-free whole genome sequencing (WGS) directly from samples such as sputum or cerebrospinal fluid. This innovation significantly reduces the time to result and enables real-time epidemiology of TB outbreaks, addressing a critical need in the field of TB surveillance and control.
The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS). It is designed against the seven major lineages of TB, covering the full breadth of diversity. By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
"The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance," said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN. "This innovative panel not only streamlines the workflow for healthcare professionals and researchers but also enables the real-time tracking of TB outbreaks, a crucial aspect in combating the spread of this devastating disease and managing the growing threat of drug-resistant TB."
"Innovative aspects of this workflow are the whole genome analysis from clinical samples, avoidance of the culturing delay, and inclusion of genetic diversity," stated Daniela Maria Cirillo, MD, PhD, Head of Emerging Bacterial Pathogens Unit at IRCCS San Raffaele Scientific Institute, Milan, Italy.
The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment. The panel covers all AMR-related genes, allowing for the identification of resistant TB strains, including multidrug-resistant tuberculosis (MDR-TB), which is caused by bacteria that do not respond to the most effective first-line TB drugs.

QGEN

QIAGEN Expands Tuberculosis Portfolio With New NGS Panel To Support Real-Time Surveillance And Combat Antimicrobial Resistance

MORN

Morningstar Q1 Revenue $542.8M, Up 13.2%; Adj. EPS $1.73

Northern Star Investment II agrees to settle SEC charges on filing misstatements

Northern Star Investment II (NSTB) has released an update. Northern Star Investment Corp. II has announced that, since it will not achieve an initi...

Northern Star II Announces Imminent Liquidation and Delisting

Northern Star Investment II (NSTB) has released an update to notify the public and investors about an entry into a material definitive agreement. T...